多发性硬化症患者接受那他珠单抗治疗期间的CD4/CD8比值。
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
作者信息
Carotenuto Antonio, Scalia Giulia, Ausiello Francesco, Moccia Marcello, Russo Cinzia Valeria, Saccà Francesco, De Rosa Anna, Criscuolo Chiara, Del Vecchio Luigi, Brescia Morra Vincenzo, Lanzillo Roberta
机构信息
Department of Neurosciences, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.
Citometria, Immunologia Cellulare e dei Trapianti D.A.I. di Medicina Trasfusionale e CEINGE- Biotecnologie Avanzate, Centro di riferimento Regione Campania per la Biologia Molecolare Clinica, la Diagnostica di Malattie Congenite del Metabolismo e delle Malattie Rare, Italy.
出版信息
J Neuroimmunol. 2017 Aug 15;309:47-50. doi: 10.1016/j.jneuroim.2017.05.006. Epub 2017 May 12.
Although improved, the risk of progressive multifocal leukoencephalopathy is a constant threat for patient affected by multiple sclerosis treated with natalizumab. We performed a 24months longitudinal study aimed to evaluate the total WBC and lymphocytes subsets modifications and their correlations with anti-JCV antibody index after 1 and 2years of natalizumab treatment. Natalizumab induced an increase of WBC, total and C19+ lymphocytes together with a decrease of CD3+, CD4+ T lymphocytes and CD4/CD8 ratio, which was positively related to anti-JCV antibodies index at month 0, 12 and 24. Our study confirms that lymphocytes subsets are modified under NAT therapy. Implications of lymphocyte subsets alterations in the pathogenesis of PML are under analyses.
尽管有所改善，但进行性多灶性白质脑病的风险对于接受那他珠单抗治疗的多发性硬化症患者来说仍然是持续存在的威胁。我们进行了一项为期24个月的纵向研究，旨在评估那他珠单抗治疗1年和2年后白细胞总数和淋巴细胞亚群的变化及其与抗JCV抗体指数的相关性。那他珠单抗导致白细胞、总淋巴细胞和C19 +淋巴细胞增加，同时CD3 +、CD4 + T淋巴细胞和CD4/CD8比值降低，这在第0、12和24个月时与抗JCV抗体指数呈正相关。我们的研究证实，在那他珠单抗治疗下淋巴细胞亚群会发生改变。目前正在分析淋巴细胞亚群改变在进行性多灶性白质脑病发病机制中的意义。
Zotero 插件